X4 Pharmaceuticals (XFOR) Receives Strong Buy Upgrade: Implications for the Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 22 2025
0mins
Source: NASDAQ.COM
X4 Pharmaceuticals Upgrade: X4 Pharmaceuticals (XFOR) has received a Zacks Rank #1 (Strong Buy) upgrade, indicating a positive outlook due to rising earnings estimates, which are crucial for stock price movements.
Zacks Rating System: The Zacks rating system, based on earnings estimate revisions, has a strong track record, with Zacks Rank #1 stocks averaging a +25% annual return since 1988, highlighting its effectiveness for investors.
Earnings Estimates Increase: Over the past three months, analysts have raised their earnings estimates for X4 Pharmaceuticals by 61.3%, reflecting an improvement in the company's business outlook.
Market Positioning: The upgrade places X4 Pharmaceuticals in the top 5% of Zacks-covered stocks, suggesting potential for significant price movement in the near term due to favorable earnings revisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XFOR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XFOR
Wall Street analysts forecast XFOR stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.940
Low
7.00
Averages
57.75
High
120.00
Current: 3.940
Low
7.00
Averages
57.75
High
120.00
About XFOR
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
X4 Pharmaceuticals Grants Inducement Awards to New Employees
- Equity Incentive Plan: On July 6, 2026, X4 Pharmaceuticals granted options to purchase 750,000 shares of common stock to new employees under the 2019 Inducement Equity Incentive Plan, aimed at attracting new talent and enhancing company competitiveness.
- Option Details: The options have an exercise price of $4.03 per share, equal to the closing price on the grant date, with a ten-year term and a four-year vesting schedule to ensure long-term employee retention.
- Market Compliance: This inducement measure complies with Nasdaq Listing Rule 5635(c)(4) and has been approved by X4's Compensation Committee, demonstrating the company's commitment to compliance and transparency.
- Company Background: X4 Pharmaceuticals focuses on developing innovative therapies for rare hematology diseases, having successfully launched the oral CXCR4 antagonist mavorixafor, which is approved in the U.S. and EU, showcasing its leadership in the biopharmaceutical sector.
See More
X4 Pharmaceuticals Appoints Kelly Gold to Board of Directors
- New Board Member: X4 Pharmaceuticals appointed Kelly Gold as an independent director effective July 1, 2026, enhancing the company's strategic and financial expertise, which is expected to drive business growth in rare hematology diseases.
- Rich Financial Background: Ms. Gold previously served as CFO at CAMP4 Therapeutics, overseeing corporate finance, investor relations, and strategic planning, and her experience is anticipated to provide crucial support for X4's operations in capital markets.
- Biotech Industry Experience: During her tenure at Biogen, Ms. Gold provided financial leadership for rare disease programs and developed long-term strategies, and her expertise is expected to aid X4's further development in the biotech sector.
- Advancing Innovative Therapies: X4 Pharmaceuticals focuses on developing innovative therapies for rare hematology diseases, and Ms. Gold's addition is expected to facilitate the commercialization of mavorixafor, enhancing the company's competitiveness in the market.
See More
X4 Pharmaceuticals Q1 Earnings Beat Expectations
- Earnings Highlights: X4 Pharmaceuticals reported a Q1 GAAP EPS of -$0.16, beating expectations by $0.04, indicating a slight improvement in profitability despite remaining in the red.
- Revenue Performance: The company generated $2.71 million in revenue for the quarter, a significant 90.6% year-over-year decline, yet it exceeded market expectations by $0.88 million, suggesting some resilience in sales amidst challenges.
- Cash Position: As of March 31, 2026, X4's cash position stood at $233.7 million, ensuring sufficient funding for future R&D and operations, which bolsters market confidence in its ongoing viability.
- Market Outlook: Presenting at the Guggenheim Securities Biotech Summit, X4 Pharmaceuticals highlighted its funded path to FDA approval, demonstrating its proactive approach to navigating challenges while seeking growth opportunities in the biotech sector.
See More
X4 Pharmaceuticals Completes EU Approval for XOLREMDI®
- Clinical Trial Progress: X4 Pharmaceuticals is on track to complete enrollment for its pivotal 4WARD Phase 3 trial by Q3 2026, with over 110 active clinical trial sites globally, enhancing patient recruitment and regulatory alignment, demonstrating the company's ongoing commitment to treating rare hematologic disorders.
- Product Approval: The European Commission has granted marketing authorization for XOLREMDI® (Mavorixafor) for the treatment of patients with WHIM syndrome, making it the only authorized treatment in this area, which is expected to generate up to €226 million in milestone payments and double-digit royalties on future sales.
- Financial Performance: As of March 31, 2026, the company reported a cash position of $233.7 million, with revenue declining to $2.7 million year-over-year; however, through reduced R&D and administrative expenses, net loss decreased to $20.2 million, reflecting positive cost control measures.
- Market Outlook: Mavorixafor, as a CXCR4 antagonist, has the potential to improve the quality of life for chronic neutropenia patients, which is expected to drive long-term growth for the company in the rare hematology market, particularly through its commercialization partnership with Norgine.
See More
X4 Pharmaceuticals Grants Inducement Awards to New Employees
- Equity Incentive Plan: On March 31, 2026, X4 Pharmaceuticals granted 32,000 stock options to new employees under the 2019 Inducement Equity Incentive Plan, aimed at attracting and retaining talent while enhancing the company's competitive edge in rare hematology diseases.
- Option Details: The options have an exercise price of $4.13 per share, equal to the closing price on the grant date, with a ten-year term and a four-year vesting schedule, reflecting the company's commitment to long-term employee contributions.
- Clinical Trial Progress: X4 is conducting a pivotal global Phase 3 trial evaluating its CXCR4 antagonist mavorixafor for chronic neutropenic disorders, with the FDA granting Fast Track designation, indicating strong market anticipation for the drug.
- Company Vision: Focused on developing innovative therapies to improve the lives of patients with rare hematology diseases, X4 leverages expertise in immune system disorders and CXCR4 biology to address significant unmet medical needs and drive long-term growth.
See More
X4 Pharmaceuticals Q4 Earnings Beat Expectations
- Earnings Highlights: X4 Pharmaceuticals reported a Q4 GAAP EPS of -$0.22, beating expectations by $0.13, indicating a positive trend in improving profitability despite still being in the red.
- Revenue Surge: The company achieved Q4 revenue of $2.57 million, a 79.7% year-over-year increase, surpassing market expectations by $0.84 million, suggesting strong product demand and enhanced market acceptance, potentially laying the groundwork for future growth.
- Stock Price Reaction: Following the earnings release, X4 Pharmaceuticals' shares rose by 4% in after-hours trading, reflecting a positive investor response to the company's performance, which may bolster market confidence and attract more investor interest.
- Industry Outlook: X4 Pharmaceuticals presented its future outlook at the Guggenheim Securities Biotech Summit, emphasizing its funded path to FDA approval, indicating the company's strategic positioning and potential growth opportunities in the biotech sector.
See More
X4 Pharmaceuticals Grants Inducement Awards to New Employees
- Equity Incentive Plan: On July 6, 2026, X4 Pharmaceuticals granted options to purchase 750,000 shares of common stock to new employees under the 2019 Inducement Equity Incentive Plan, aimed at attracting new talent and enhancing company competitiveness.
- Option Details: The options have an exercise price of $4.03 per share, equal to the closing price on the grant date, with a ten-year term and a four-year vesting schedule to ensure long-term employee retention.
- Market Compliance: This inducement measure complies with Nasdaq Listing Rule 5635(c)(4) and has been approved by X4's Compensation Committee, demonstrating the company's commitment to compliance and transparency.
- Company Background: X4 Pharmaceuticals focuses on developing innovative therapies for rare hematology diseases, having successfully launched the oral CXCR4 antagonist mavorixafor, which is approved in the U.S. and EU, showcasing its leadership in the biopharmaceutical sector.
See More
X4 Pharmaceuticals Appoints Kelly Gold to Board of Directors
- New Board Member: X4 Pharmaceuticals appointed Kelly Gold as an independent director effective July 1, 2026, enhancing the company's strategic and financial expertise, which is expected to drive business growth in rare hematology diseases.
- Rich Financial Background: Ms. Gold previously served as CFO at CAMP4 Therapeutics, overseeing corporate finance, investor relations, and strategic planning, and her experience is anticipated to provide crucial support for X4's operations in capital markets.
- Biotech Industry Experience: During her tenure at Biogen, Ms. Gold provided financial leadership for rare disease programs and developed long-term strategies, and her expertise is expected to aid X4's further development in the biotech sector.
- Advancing Innovative Therapies: X4 Pharmaceuticals focuses on developing innovative therapies for rare hematology diseases, and Ms. Gold's addition is expected to facilitate the commercialization of mavorixafor, enhancing the company's competitiveness in the market.
See More
X4 Pharmaceuticals Q1 Earnings Beat Expectations
- Earnings Highlights: X4 Pharmaceuticals reported a Q1 GAAP EPS of -$0.16, beating expectations by $0.04, indicating a slight improvement in profitability despite remaining in the red.
- Revenue Performance: The company generated $2.71 million in revenue for the quarter, a significant 90.6% year-over-year decline, yet it exceeded market expectations by $0.88 million, suggesting some resilience in sales amidst challenges.
- Cash Position: As of March 31, 2026, X4's cash position stood at $233.7 million, ensuring sufficient funding for future R&D and operations, which bolsters market confidence in its ongoing viability.
- Market Outlook: Presenting at the Guggenheim Securities Biotech Summit, X4 Pharmaceuticals highlighted its funded path to FDA approval, demonstrating its proactive approach to navigating challenges while seeking growth opportunities in the biotech sector.
See More
X4 Pharmaceuticals Completes EU Approval for XOLREMDI®
- Clinical Trial Progress: X4 Pharmaceuticals is on track to complete enrollment for its pivotal 4WARD Phase 3 trial by Q3 2026, with over 110 active clinical trial sites globally, enhancing patient recruitment and regulatory alignment, demonstrating the company's ongoing commitment to treating rare hematologic disorders.
- Product Approval: The European Commission has granted marketing authorization for XOLREMDI® (Mavorixafor) for the treatment of patients with WHIM syndrome, making it the only authorized treatment in this area, which is expected to generate up to €226 million in milestone payments and double-digit royalties on future sales.
- Financial Performance: As of March 31, 2026, the company reported a cash position of $233.7 million, with revenue declining to $2.7 million year-over-year; however, through reduced R&D and administrative expenses, net loss decreased to $20.2 million, reflecting positive cost control measures.
- Market Outlook: Mavorixafor, as a CXCR4 antagonist, has the potential to improve the quality of life for chronic neutropenia patients, which is expected to drive long-term growth for the company in the rare hematology market, particularly through its commercialization partnership with Norgine.
See More
X4 Pharmaceuticals Grants Inducement Awards to New Employees
- Equity Incentive Plan: On March 31, 2026, X4 Pharmaceuticals granted 32,000 stock options to new employees under the 2019 Inducement Equity Incentive Plan, aimed at attracting and retaining talent while enhancing the company's competitive edge in rare hematology diseases.
- Option Details: The options have an exercise price of $4.13 per share, equal to the closing price on the grant date, with a ten-year term and a four-year vesting schedule, reflecting the company's commitment to long-term employee contributions.
- Clinical Trial Progress: X4 is conducting a pivotal global Phase 3 trial evaluating its CXCR4 antagonist mavorixafor for chronic neutropenic disorders, with the FDA granting Fast Track designation, indicating strong market anticipation for the drug.
- Company Vision: Focused on developing innovative therapies to improve the lives of patients with rare hematology diseases, X4 leverages expertise in immune system disorders and CXCR4 biology to address significant unmet medical needs and drive long-term growth.
See More
X4 Pharmaceuticals Q4 Earnings Beat Expectations
- Earnings Highlights: X4 Pharmaceuticals reported a Q4 GAAP EPS of -$0.22, beating expectations by $0.13, indicating a positive trend in improving profitability despite still being in the red.
- Revenue Surge: The company achieved Q4 revenue of $2.57 million, a 79.7% year-over-year increase, surpassing market expectations by $0.84 million, suggesting strong product demand and enhanced market acceptance, potentially laying the groundwork for future growth.
- Stock Price Reaction: Following the earnings release, X4 Pharmaceuticals' shares rose by 4% in after-hours trading, reflecting a positive investor response to the company's performance, which may bolster market confidence and attract more investor interest.
- Industry Outlook: X4 Pharmaceuticals presented its future outlook at the Guggenheim Securities Biotech Summit, emphasizing its funded path to FDA approval, indicating the company's strategic positioning and potential growth opportunities in the biotech sector.
See More
